Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum

2012 ◽  
Vol 132 (3) ◽  
pp. 726-731 ◽  
Author(s):  
Jan Brun ◽  
Douglas J. Mahoney ◽  
Fabrice Le Boeuf ◽  
Charles Lefebvre ◽  
Cina A. Sanaei ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Mouse Models ◽  
Xeroderma Pigmentosum ◽  
Skin Tumors

scholarly journals Biological Activity of an Intravenous Preparation of Human Vaccinia Immune Globulin in Mouse Models of Vaccinia Virus Infection

2005 ◽  
Vol 49 (7) ◽  
pp. 2634-2641 ◽  
Author(s):  
Jeffry D. Shearer ◽  
Linda Siemann ◽  
Mary Gerkovich ◽  
Robert V. House
Keyword(s):  
Biological Activity ◽  
Mortality Rate ◽  
Virus Infection ◽  
Vaccinia Virus ◽  
Mouse Models ◽  
Immune Globulin ◽  
Scid Mice ◽  
Prolonged Survival ◽  
Murine Models ◽  
Lesion Formation

ABSTRACT The biological activity of a new intravenous (i.v.) preparation of human vaccinia immune globulin (VIGIV) was evaluated in two mouse models of vaccinia virus (VV) infection. In a mouse tail lesion model, female CD-1 mice were inoculated i.v. with 7 × 104 PFU of VV to produce >10 lesions per tail 8 days later. In a mouse lethality model, female severe combined immunodeficient (SCID) mice were inoculated i.v. with 3 × 104 PFU of VV to produce 100% mortality within 45 days. The ability of VIGIV to reduce tail lesion formation in CD-1 mice and mortality in SCID mice was determined by (i) pretreatment of a lethal VV dose with VIGIV prior to i.v. inoculation into SCID mice and (ii) i.v. administration of VIGIV to CD-1 and SCID mice the day before and up to 8 days after VV infection. VIGIV reduced the proportion of CD-1 mice with >10 tail lesions in a dose-related manner when VIGIV was given 1 day before and up to 1 day after VV inoculation. The pretreatment of VV with VIGIV prolonged survival and decreased mortality. VIGIV (100 and 400 mg/kg) prolonged survival when given up to 4 days after VV inoculation, and the 400-mg/kg dose reduced the mortality rate by 80% when given the day before or immediately after VV inoculation. The biological activity of VIGIV was demonstrated in both the immunocompetent and immunocompromised murine models. The timing of treatment relative to VV inoculation appeared to be important for the demonstration of VIGIV's biological activity.

Mouse Models for Xeroderma Pigmentosum Group A and Group C Show Divergent Cancer Phenotypes

2008 ◽  
Vol 68 (5) ◽  
pp. 1347-1353 ◽  
Author(s):  
Joost P.M. Melis ◽  
Susan W.P. Wijnhoven ◽  
Rudolf B. Beems ◽  
Marianne Roodbergen ◽  
Jolanda van den Berg ◽  
...  
Keyword(s):  
Mouse Models ◽  
Xeroderma Pigmentosum ◽  
Group A ◽  
Cancer Phenotypes ◽  
Xeroderma Pigmentosum Group A

scholarly journals Xeroderma Pigmentosum in Children: Report of 4 Cases

Health Scope ◽  
2020 ◽  
Vol 9 (4) ◽  
Author(s):  
Ghasem Miri-Aliabad ◽  
Leila Asgarzadeh
Keyword(s):  
Xeroderma Pigmentosum ◽  
Genetic Disorder ◽  
Skin Aging ◽  
Incidence Rates ◽  
Skin Tumors ◽  
The Body ◽  
Malignant Skin Tumors ◽  
Malignant Skin ◽  
Defective Dna Repair ◽  
Autosomal Recessive Pattern

: Xeroderma pigmentosum (XP) is a rare genetic disorder inherited in an autosomal recessive pattern. Patients with XP are extremely sensitive to ultraviolet (UV) radiation that leads to defective DNA repair. People with XP often suffer from problems in the eyes, face, neck, and other areas of the body, frequently exposed to sunlight. It is characterized by photosensitivity, dry skin, pigmentary changes of the skin, premature skin aging, and a considerable increase in incidence rates of malignant skin tumors. There is no cure for XP. In this article, we have described four patients from two families, three of whom had malignant skin tumors.

ONCOGENE ACTIVATION IN ULTRAVIOLET-INDUCED SKIN TUMORS FROM NORMAL INDIVIDUALS AND XERODERMA PIGMENTOSUM PATIENTS

1992 ◽  
pp. 386-391
Author(s):  
Alain Sarasin ◽  
Caroline Robert-Knebelmann ◽  
Leela Daya-Grosjean ◽  
Alvaro Margulis ◽  
Mohamed Zghal
Keyword(s):  
Xeroderma Pigmentosum ◽  
Skin Tumors ◽  
Normal Individuals ◽  
Oncogene Activation

Oncogene Activation in Xeroderma Pigmentosum Skin Tumors

1989 ◽  
pp. 597-602
Author(s):  
Leela Daya-Grosjean ◽  
Alice de Miranda ◽  
Horacio Suarez ◽  
Bertrand Chretien ◽  
Marie-Françoise Avril ◽  
...  
Keyword(s):  
Xeroderma Pigmentosum ◽  
Skin Tumors ◽  
Oncogene Activation

Infrequent mutation of theras genes in skin tumors of xeroderma pigmentosum patients in Japan

1992 ◽  
Vol 50 (3) ◽  
pp. 382-385 ◽  
Author(s):  
Kanji Ishizaki ◽  
Tohru Tsujimura ◽  
Masanao Nakai ◽  
Chikako Nishigori ◽  
Kenji Sato ◽  
...  
Keyword(s):  
Xeroderma Pigmentosum ◽  
Skin Tumors

Activation of oncogenesis in skin tumors from a repair-deficient syndrome, xeroderma pigmentosum

1990 ◽  
Vol 234 (6) ◽  
pp. 425
Author(s):  
A. Sarasin ◽  
H.G. Suarez ◽  
A. Miranda ◽  
C. Drougard ◽  
L. Daya-Grosjean
Keyword(s):  
Xeroderma Pigmentosum ◽  
Skin Tumors
Sign in / Sign up

Export Citation Format

Share Document